Summary An open, prospective, observational study was performed to assess efficacy and adverse-event profile of topiramate as add-on therapy in epilepsy. Outpatient neurology clinics from 11 general hospitals in Greece participated in the study. In total, 211 patients with treatment resistant partial-onset seizures who met the inclusion criteria, were studied. After baseline evaluation, topiramate was given at a target dose of 200 mg/day over a 1-month titration period. In the subsequent maintenance period, the topiramate dose could be varied according to the clinical results. Patients were followed for in total 6 months, with monthly visits and regular physical, neurological and laboratory examinations. Seizure frequencies
Introduction
Monotherapy with one antiepileptic drug (AED), and even combination therapy with two or more AEDs together, quite often fail to produce adequate seizure relief in patients with epilepsy. New AEDs have become available over the past decade, providing new treatment options, and topiramate appears to be one of the promising examples. Topiramate is authorised for the adjuvant treatment of partial onset seizures with or without secondary generalisation, primary generalised tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. In comparison with other AEDs, it ranks among the most efficacious as was shown in a meta-analysis. 1 The number of patients to be treated, in order to obtain at least 50% reduction in seizure frequency, was between six and nine for other new AEDs such as tiagabine, zonisamide, lamotrigine and gabapentin, but was only three for topiramate. 2 Randomised placebo-controlled studies 3, 4 showed that the topiramate dose required to produce these effects, was in the range of 200-400 mg/day. In recent studies, topiramate was also found efficacious as monotherapy. 5, 6 A double-blind randomised trial comparing topiramate (100 or 200 mg/day) with either carbamazepine or valproate, showed that topiramate was as effective as these older AEDs. 7 Consequently topiramate received official approval for use as monotherapy in most European countries.
Regarding everyday clinical practice, it is good to keep in mind that published data on topiramate addon treatments were almost exclusively gathered in randomised controlled studies. Such studies applied fixed doses and predetermined treatment regimens that are assigned to patients on the basis of a randomisation schedule rather than taking the patient's personal needs into account. 3, [8] [9] [10] [11] [12] Clinical practice on the other hand, focuses on the individual patient and aims at optimising his or her personal therapy. Considerable differences in drug susceptibility are known to exist from patient to patient, and pragmatic titration is the usual approach to determine which dose balances best antiepileptic efficacy and adverse event profile in a particular case.
We decided to investigate the everyday use of topiramate in adult epilepsy patients with therapyresistant partial onset seizures, selected as outpatients of non-specialised neurology clinics of general hospitals.
Patients and methods

Patients
Male and female patients, 18 years of age and over, were eligible if they had experienced at least four partial-onset seizures with or without secondary generalisation, according to the International Classification of Seizures, 13 in the 2 months preceding study entry. Patients had to be treated with one or more AEDs during the immediate pre-trial period. Female patients of childbearing potential had to use acceptable contraceptive methods during the trial; pregnant or breast-feeding women could not be included. Patients were excluded if they had a treatable cause of seizures, progressive neurological disorder, or a history of generalised status epilepticus in the past 3 months. Patients with a medical or social state that would influence their reliable participation, or who were unable to complete the diary or take their medication (not even with available help), were also excluded.
The study was conducted in accordance with the principles of the Declaration of Helsinki. After approval by the applicable Institutional Review Board, written informed consent was obtained from each patient prior to study entry or any studyrelated procedures. 
Study design
A prospective, open-label study was set up in the outpatient general neurology (not specialised in epileptology) clinics of 11 general hospitals, in Greece. Co-ordination and supervision of these clinics was performed by specialised epilepsy centres which were involved in the conduct of the trial. Patients were followed over 6 months of topiramate therapy, i.e., a 1-month initial titration period and a subsequent 5-month maintenance period. After obtaining informed consent, data from the last 7 weeks under the existing antiepileptic treatment were collected (baseline period). Topiramate, given as morning and evening doses, was added to the treatment regimen and was started at 50 mg/day. Titration was performed with weekly dose increments of 50 mg/ day to reach the initial target dose of 200 mg/day at the end of the titration period. During the maintenance period, the dose of topiramate could be increased or decreased according to the investigator's judgement. Patients were followed with once monthly visits to the clinic. Physical and neurological examinations were performed each visit, laboratory examinations (haematology and blood biochemistry) every 3 months. Patients used a diary to keep track of their seizures. The study focussed on the efficacy, safety and side effects of the various antiepileptic treatment regimens in combination with topiramate.
Statistical methods
The primary intent-to-treat analysis included all patients that entered the study (='All patients'), a secondary analysis was performed on those patients who completed the trial (='Completers'). No major differences appeared to exist between the results of these analyses, though the one with all patients showed more fluctuations over time, and had a larger standard deviation for a number of parameters, than the one with only the completers. Statistical analyses were performed using S-plus. Seizures during the 7-week baseline period were arithmetically corrected for the longer observation time to produce a baseline monthly (i.e., 4-week) seizure rate. Most of the results were analysed with simple descriptive statistics. Where applicable Wilcoxon's two-sample test, Chi-square test, ANOVA or Student's t-test were performed. The level of significance was set at p < 0.05. In case of multiple comparisons a correction according to Bonferoni was applied.
Results
Study population
The 11 participating centres enrolled 211 patients altogether. Thirty-one patients (15%) could not be evaluated at the final visit due to early discontinuation (dropout). Reasons for early discontinuation were: adverse events (16 patients), lost to follow up (6), insufficient response/exacerbation (3), withdrawal of informed consent (2), non-compliance (1), asymptomatic/cured (1), and not specified (2) . Baseline characteristics were in accordance with general expectations: mean age was 37.0 years (S.D. 15.3; range 13-77), 49% of patients were female, no systematic age difference was found between male and female patients.
Topiramate dose
The target dose, set for the end of the initial titration period, was 200 mg/day. The average dose reached at the end of this 1-month period appeared to be 187 mg/day (S.D. = 73, range 50-600, n = 208).
During the subsequent maintenance period, the dose was further increased in 65% of patients while a reduction of the dose occurred in less than 3% of patients. Three months after the initial titration period the topiramate dose had risen to a mean of 285 mg/day (S.D. 107; n = 186; median 300 mg/ day). The dose remained at that level till the end of the study, at month 6 a mean dose of 298 mg/day was found (S.D. 112; n = 178; median 300 mg/day). Fig. 1 depicts the percent of patients for the doses used at 1, 3 and 6 months after initiation of the topiramate treatment. At the end of the study (month 6) 86.5% of patients were satisfactorily treated with a dose between 200 and 400 mg/day (88.9% at month 3). Dose figures remained more or Figure 1 Topiramate dose distribution categorised per 50 or 100 mg/day dose intervals, at various points in time after adding topiramate to the treatment regimen. Numbers of patients involved were 207, 189 and 178 at months 1, 3 and 6, respectively. less stable between months 3 and 6, so it appears that the optimal dose was generally achieved within 3 months.
Other AEDs
Of the included patients, 141 used one other AED, 49 used two other AEDs and 14 patients used three other AEDs besides topiramate (seven patients were eventually treated with topiramate monotherapy). The most common AEDs in topiramate combination therapy were carbamazepine (CBZ; 48 patients), oxcarbazepine (OCB; 41), valproate (VPA; 30), and phenytoin (PHE; 12). With patients using two other AEDs, the combination VPA + CBZ (eight patients), CBZ + lamotrigine (LTG; 9), and VPA + OCB (seven) were the most common. No combination occurred more than twice in the patients using three AEDs together with topiramate. Fig. 2 presents the number of monthly seizures over the preceding month for each visit. During the first months of treatment, the graph for all patients differs from the one of the completers, which is mainly due to one patient who had a very high seizure frequency before he discontinued participating in the trial. The completers' graph, which is a better reflection of treatment effects over time, clearly indicates that seizure frequency dropped from the very moment topiramate treatment was installed. After the initial titration period the drop in seizure frequency further progressed until it levelled off after 2-3 months at a level of 33-39% of baseline frequency.
Efficacy
Seizure frequency
Cumulative seizure frequencies over the first 3 months of topiramate therapy, and over the whole study period, were calculated and compared with baseline data (Table 1 ). The median monthly seizure rate decreased from 4.0 at baseline to 1.3 over 3 months, and to 1.0 over 6 months treatment (results not shown). Monthly seizure frequencies over 3 and 6 months were statistically significantly lower than at baseline. Table 2 indicates the number of patients with a !50% reduction in seizure frequency (the responders) over the indicated treatment period. Adding topiramate to the treatment regimen resulted in an increasing number of responders over time which, after fine-tuning the dosage, appeared to stabilise at 83-85%, 4 months after start of treatment.
Response rate
Seizure freedom
All patients experienced seizures during the 7-week baseline period. During the course of the trial the number of patients with a seizure-free month rose gradually. Like the reduction in seizure frequency and the number of responders, this variable levelled off over time, i.e., to 51-55% of patients in the last 3 months of the study (Fig. 3) .
Also, an analysis was made of the length of the seizure-free period at the end of the trial. It appeared that no patient had been seizure-free from the very start of the titration, but 12% had remained seizure-free during the whole maintenance period (5 months), and almost 30% remained seizure-free for at least 3 months. Figure 2 Mean seizure frequency over the previous month, assessed at the various monthly visits. Data are given for all patients (n = 211) and for the completers (n = 180). Symbols indicate statistical significance for the completers' graph (significance for the all patients graph were similar) and refer to Wilcoxon's test with Bonferoni correction.
y p < 0.001 vs. baseline. p-values refer to the change in seizure frequency from baseline using Wilcoxon test (two-sided).
Safety/tolerability
Overall, 107 subjects (51%) experienced at least one adverse event (AE) during topiramate treatment. AEs reported by !2% of the patients are presented in Table 3 , along with the putative relation to the topiramate treatment as assessed by the investigator ('possibly related' and 'related' were combined, the remaining cases were assessed as 'not related'). Weight reduction was the most frequently mentioned AE (13% of patients, see Table 3 ) but five of these patients explicitly mentioned that they did not want to lower the topiramate dose because of that event.
Two serious adverse events were reported in this study. The first one, a case of pneumothorax, was interpreted as not related to the use of topiramate. The second one, status epilepticus, was ascribed to the underlying disorder.
Abnormalities found during the physical examination at study entry either remained stable or disappeared. The same holds for the abnormalities at the initial neurological examination, but in one patient, signs of cerebellar dysfunction, in another one signs of extrapyramidal dysfunction, were later found to have developed during the trial. The investigators did not attribute either of these cases to the use of topiramate. No deviating haematological or biochemical values were detected following lab analyses.
Discussion
This study was undertaken to collect and summarise ongoing practical experience with topiramate and, in doing so, to guide general neurologists who consider adding this drug to an existing antiepileptic treatment regimen. The study focused on the efficacy and side effects in patients with partial-onset seizures. Study centres were general neurology hospital-based outpatient clinics, rather than specialised epilepsy clinics, and were selected to best mimic everyday clinical practice. Efficacy and safety data were monitored on a monthly basis for 6 months, so more often than can usually be achieved in neurological practice.
Efficacy assessment basically relied on seizure counts that were normalised to monthly (28-day) seizure frequencies. Three efficacy variables were derived from these counts. First, the change in monthly seizure frequency as compared to the baseline (no topiramate treatment) was assessed for each visit on treatment. Second, the number of patients with an at least 50% drop in their monthly seizure frequency relative to baseline was calculated. This yielded the number and percentage of therapy 'responders'. Third, the number of seizurefree patients was assessed at each visit and the length of the seizure-free period at trial completion was calculated retrospectively for each individual. These three parameters all indicated that the Table 2 Number of responders (patients with at least a 50% reduction in monthly seizure frequency as compared to baseline) vs. total number of observations at the various follow-up visits after start of the topiramate treatment.
Duration of treatment
Percent responders (number of observations) Figure 3 Percent of patients reporting a seizure-free month at the various visits after the start of topiramate add-on treatment (completers, n = 180).
Table 3
Adverse events that were reported by more than 2% of all patients (n = 211) and the number of these adverse events that were believed to be related or possibly related to the use of topiramate.
Adverse event Total occurrence (Possibly) related decrease  27  13  21  10  Somnolence  23  11  21  10  Paraesthesia  22  10  9  4  Insomnia  9  4  1  0  Emotional lability  9  4  1  0  Dizziness  8  4  7  3  Fatigue  7  3  4  2  Anxiety  7  3  2  1  Nervousness  7  3  4  2  Headache  6  3  6  3  Anorexia  6  3  5  2  Depression  6  3  5  2 efficacy of the treatment improved from the moment that topiramate co-treatment was installed. The antiepileptic effect rose during the first months and became stable after 3 months of topiramate treatment. Dose adaptations may have played a significant role in this effect. Topiramate had to be titrated to an initial 200 mg/day target dose, after which the dose could be further adjusted to the patient's need. In practice, however, up to 60% of patients had not yet reached this dose after the 1-month initial titration period (Fig. 1) . Further dose increments during the second and third months of treatment were of such extent that they might well explain the continued regression in seizure counts. No substantial dose changes were seen beyond the first 3 months of treatment. At study completion, 89% of patients were using topiramate in the recommended dose range (i.e., 200-400 mg/day).
14 Mean and median topiramate doses happened to be right in the middle of this range (i.e., 298 and 300 mg/ day, respectively).
The mean number of monthly seizures stabilised at 33-39% of baseline, while the monthly seizure frequency over the first 3 months decreased to 52% (mean) or 33% (median) of baseline values. Over the full 6-month treatment period, monthly seizure rate was even more reduced to 44% (mean) or 25% (median) of baseline. In a recent meta-analysis of six double-blind, randomised, placebo-controlled studies, Peeters et al. 15 found a reduction to 55-62% (median) of baseline values depending on the dose (200-800 mg/day) and duration (8-12 weeks maintenance after 3-8 weeks initial titration) of topiramate treatment. Our results compared well with these data, showing an even more pronounced effect of topiramate than the meta-analysis. A possible explanation for this could be that, in contrast to these randomised controlled trials, our study allowed titration to an individual optimal dose, thus enabling patients to benefit better from the newly added topiramate treatment. A potential difference in patient selection, however, cannot be ruled out as a contributing factor. The study outcome could then be interpreted in that we might have included less severe cases and/or patients who were less resistant to the effect of antiepileptic medication than in the randomised controlled studies.
The response rate to topiramate also compared well with the one found in randomised controlled studies with AED refractory patients. 15, 16 In our study, the number of responders stabilised at around 80% while in the meta-analysis response to topiramate varied from 24 to 44% of patients using doses from 200 to 600 mg/day. 15 In a comprehensive randomised, placebo-controlled study, Guberman et al. 16 found a 44% reduction in seizure frequency and 45% of patients responding over a 12-week evaluation period. During the last 4 weeks of the latter study (maintenance phase) figures improved to 53% seizure reduction and 58% responders. In our study, mean monthly seizure frequency dropped 50% over a 6-month period and 67% over the last 4 weeks when 83% of patients were still treatment responders.
Frommonth3onwards,thenumberofpatientswith a seizure-free month stabilised at 50-55%, 30% of patients remained seizure-free till the end of the study. About 12.5% of patients were without any seizures during the entire 5-month maintenance period. This data too compared well with the 5% seizurefree patients in Reife's pooled analysis. 17 Our results with respect to seizure reduction, number of responders, number of seizure-free patients, and duration of seizure-free periods, all suggested that a neurologist who adds topiramate to the antiepileptic treatment regimen, may expect better results than those reported from randomised controlled studies. Apparently, response rates are higher in routine clinical practice than in the tertiary referral centres that are usually involved in the performance of randomised controlled studies. It is not clear whether this is due to patient selection, individual versus randomised topiramate dosing, or other causes.
The number of patients who discontinued this trial prematurely, was rather low (15%) as compared to many published trials on the use of AEDs in adults with partial onset seizures (e.g., [18] [19] [20] . The number of withdrawals due to adverse events (7%) was as good as that reported from randomised controlled trials, i.e., a dose-dependent withdrawal rate of 7-16% (topiramate doses of 200-600 mg/day). 15 Adverse events reported in our study were the ones known for topiramate. Most of them were reported as 'mild'. Reports of dizziness, psychomotor slowing, confusion and speech disorder were rare and occurred less frequently than reported before. Somnolence for instance, was reported considerably less often (11%) than in the pooled analysis (30%) 15 or in the manufacturer's data file (29%).
14 Depression, emotional lability, insomnia and anxiety were reported in our study at a low rate, but were not mentioned in earlier publications. 15, 16 However, this may very well be explained by the fact that these publications listed only those AEs occurring in over 10% of patients, whereas the cut-off in our study was laid at 2%. This again suggested that a low adverse event rate can be expected when topiramate is used in regular epilepsy patients and is titrated to a dose that, based on individual needs, balances adverse events with appropriate antiepileptic efficacy.
Conclusions
Topiramate, given as add-on therapy to patients with refractory partial-onset seizures, can be titrated individually to reach an optimal effect after 3 months. In everyday clinical practice its efficacy with respect to seizure reduction, number of therapy responders, number of seizure-free patients and number of consecutive seizure-free months, is likely to be better than would be expected from the data of published, randomised controlled trials. Adverse events occur less frequently than reported in literature, and cause therapy discontinuation only in a minority of patients.
